Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 6,311 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Advanced therapy Clear all

Conditions: Advanced Breast Cancer
Interventions: Saruparib (AZD5305), Camizestrant, Abemaciclib, Ribociclib, Palbociclib, Fulvestrant, Letrozole, Anastrozole, Exemestane; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 788 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 57
States / cities: Gilbert, Arizona • Fountain Valley, California • Glendale, California + 49 more

Conditions: Head and Neck Cancer
Interventions: cisplatin, cytochlor, tetrahydrouridine, radiation therapy; Drug · Radiation
Lead sponsor: University of Miami; Other
Eligibility: 21 Years to 120 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pancreatic Neoplasms, Bile Duct Neoplasms
Interventions: Oxaliplatin, Capecitabine, Sorafenib; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
Interventions: Biospecimen Collection, Cholestyramine, Computed Tomography, Diagnostic Imaging, Gemcitabine, Leflunomide, Magnetic Resonance Imaging; Procedure · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Head and Neck Cancer
Interventions: Cetuximab, Nab-paclitaxel, Carboplatin; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Nashville, Tennessee • Seattle, Washington

Conditions: Melanoma Neoplasms
Interventions: KU-0059436 (AZD2281)(PARP inhibitor), dacarbazine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms, Pancreas Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent, Non-Small Cell Squamous Lung Cancer, NSCLC, NSCLC, Recurrent, Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, CRC, Colorectal Cancer Metastatic, Cancer
Interventions: A2B530, xT-Onco with HLA-LOH Assay; Biological · Diagnostic Test
Lead sponsor: A2 Biotherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 8
States / cities: Gilbert, Arizona • La Jolla, California • Los Angeles, California + 5 more

Conditions: Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms, Gastrointestinal Neoplasms
Interventions: Motexafin Gadolinium; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: Docetaxel, Pertuzumab, Trastuzumab emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Charlotte, North Carolina • Houston, Texas

Conditions: Adult Solid Neoplasm
Interventions: Ixabepilone, Pharmacological Study, Temsirolimus; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
Interventions: CAB-ROR2-ADC, PD-1 inhibitor; Biological
Lead sponsor: BioAtla, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 38
States / cities: Tucson, Arizona • Duarte, California • La Jolla, California + 30 more

Conditions: Pancreatic Cancer
Interventions: DC Vaccine + Standard of Care Chemotherapy; Biological
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Ovarian Cancer
Interventions: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine, Melphalan, Stem Cell Transplant; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-small Cell Lung Cancer
Interventions: Vorinostat, Bevacizumab, Carboplatin, Paclitaxel; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Alzheimer's Disease
Interventions: Timed Planned Activity, Home Safety and Education Program; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 60 Years to 100 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pancreatic Cancer
Interventions: ISIS 2503; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 2
States / cities: Birmingham, Alabama • Lebanon, New Hampshire

Conditions: Breast Cancer
Interventions: paclitaxel, sorafenib tosylate; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Solid Tumor, Adult, Metastasis
Interventions: Palliative and Survivorship Care Model; Behavioral
Lead sponsor: Good Samaritan Hospital Medical Center, New York; Other
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: West Islip, New York

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: TG4050; Drug
Lead sponsor: Transgene; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2031
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Bladder Cancer
Interventions: Sacituzumab tirumotecan, Vinflunine, Docetaxel, Paclitaxel, Rescue medications for sacituzumab tirumotecan, Rescue medications for chemotherapy; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 19
States / cities: Newport Beach, California • Washington D.C., District of Columbia • Atlanta, Georgia + 15 more

Conditions: Preterm Birth Complication
Interventions: SENSE-plus: The Supporting and Enhancing NICU Sensory Experiences 2nd Edition (SENSE II) program, SENSE: The Supporting and Enhancing NICU Sensory Experiences 2nd Edition (SENSE II) program, Reference/ Standard of care; Behavioral · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 22 Weeks to 33 Weeks
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Solid Tumor, Adult, Mesothelioma, NSCLC
Interventions: VT3989, Nivolumab & Ipilimumab, Osimertinib, Pemetrexed/Carboplatin; Drug
Lead sponsor: Vivace Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 434 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 9
States / cities: San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 5 more

Conditions: Lung Cancer, Prostate Cancer, Neoplasm Metastasis, Bone Cancer
Interventions: Enbrel; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Lung Cancer
Interventions: epothilone D; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Cytochlor and Tetrahydrouridine as Radiosensitizers and Cisplatin Combined With Radiation Therapy in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity (Mouth) or Oropharynx (Throat)

CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer

A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer

Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients

Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer

Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of AD

ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas

Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer

Clinical Nurse Specialist Led Early Palliative Survivorship Care for Patients With Advanced Cancer

A Clinical Trial Evaluating TG4050 in Head and Neck Cancer

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

Serial Brain MRI in Hospitalized Preterm Infants

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia

Epothilone D in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Platinum-Based Chemotherapy